Articles about Drugs Controller General of India

In a significant move, the Drugs Controller General of India (DCGI) on Tuesday cleared two COVID-19 vaccines for use in children aged between five and 12 years.

Bharat Biotech's COVID-19 vaccine, COVAXIN, is likely to get the Drugs Controller General of India's (DCGI) nod for use among children aged two to 12 years.

The Drugs Controller General of India (DCGI) has granted an emergency use authorization (EUA) to Corbevax—a COVID-19 vaccine developed by Hyderabad-based Biological E—for use in children aged between 12 and 18 years.

The Drugs Controller General of India (DCGI) on Thursday granted approval for regular market sale to India's two most prevalent COVID-19 vaccines—COVAXIN and Covishield.

Molnupiravir, an antiviral medication, is projected to cost between Rs. 2,000 and Rs. 3,000 for a full treatment.

Hyderabad-based pharmaceutical company Biological E's COVID-19 vaccine Corbevex's samples were cleared by the Central Drugs Laboratory in Kasauli on Tuesday.

American firm Johnson & Johnson's COVID-19 vaccine shots, manufactured in India by Hyderabad-based Biological E, are ready for export, News18 reported.

The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) has recommended granting an emergency use authorization (EUA) to ZyCoV-D, the three-dose COVID-19 vaccine developed by Zydus Cadila, on Friday.

The Drugs Controller General of India (DCGI) has approved a proposal to conduct a study on the mixing of Covishield and COVAXIN COVID-19 vaccines.

India has been offered 7.5 million doses of Moderna's COVID-19 vaccine through the COVAX global vaccine sharing program, but it is not clear when the jabs will arrive in the country as a consensus on the indemnity clause is yet to be reached, sources said.

The use of Molnupiravir, an experimental oral drug having antiviral properties, has resulted in early recovery of COVID-19 patients with mild symptoms when compared to standard treatment during Phase III clinical trials, Hetero said on Friday citing interim data.

Pharmaceutical firm Mankind Pharma on Thursday announced that it has received approval from the Defence Research and Development Organisation (DRDO) to manufacture and market the COVID-19 drug 2-Deoxy-D-Glucose or 2-DG.

A Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) has denied permission to Pune-based Serum Institute of India (SII) for conducting clinical trials of its second COVID-19 vaccine, Covovax, in children.

Zydus Cadila, the Gujarat-based drug firm, has applied for the Emergency Use Authorization (EUA) of its COVID-19 vaccine to the Drugs Controller General of India (DCGI), the company said today.

Bharat Biotech has submitted the phase three clinical trial data for its coronavirus vaccine COVAXIN to the Drugs Controller General of India (DCGI).

India's top drug regulator - the Drugs Controller General of India (DCGI) - has given approval to carry out phase-2 clinical trials of Colchicine on COVID-19 patients.

The Drugs Controller General of India has scrapped the requirement of local trials for foreign-made coronavirus vaccines - a key move to upscale the dwindling COVID-19 vaccinations in the country.

The Drugs Controller General of India (DCGI) has approved an antibody detection kit developed by a laboratory of the Defence Research and Development Organisation (DRDO), reports say.

The Drugs Controller General of India (DCGI) has approved the emergency use of an anti-coronavirus drug developed by a laboratory of the Defence Research and Development Organisation (DRDO) to treat moderate to severe patients, reports say.

Just two days before pharma major Pfizer announced the withdrawal of its application for emergency use authorization of its COVID-19 vaccine in India, an expert panel of the country's drugs regulatory authority had recommended against granting such approval to the firm at this stage.

An expert panel, Central Drugs Standard Control Organisation, (CDSCO) on Tuesday recommended granting permission for conducting the Phase I clinical trial of an intranasal vaccine against COVID-19 developed by Bharat Biotech, official sources said.

A 42-year-old volunteer named Deepak Marawi, from Bhopal in Madhya Pradesh died nearly ten days after he participated in the clinical trial for COVAXIN held at a private hospital, its vice-chancellor said on Saturday.

The first dose of the coronavirus vaccine in India will most likely be administered on January 13, a statement from a top official of the Union Health Ministry indicated on Tuesday.

Global leaders have lauded India's leadership in scientific innovation and decisive action to combat the COVID-19 pandemic.

The Serum Institute of India (SII) and Bharat Biotech have taken a joint pledge to ensure global access of the COVID-19 vaccines developed by them.

Earlier on Sunday, the Drugs Controller General of India (DCGI) announced the issuance of emergency approval to two COVID-19 vaccines for restricted use in India: Covishield and COVAXIN.

Two COVID-19 vaccines, Covishield and COVAXIN, have been granted emergency approval for use in India, the Drugs Controller General of India (DCGI) Dr. VG Somani said on Sunday.

A government-appointed panel on Saturday recommended emergency-use authorization (EUA) to the COVID-19 vaccine developed by Hyderabad-based Bharat Biotech.

A dry run for vaccination, before the actual doses of the coronavirus vaccine are administered to people, will be held in all states and union territories today.

In a development that will soothe the coronavirus-battered nation, the Central Drugs Standard Control Organization (CDSCO) panel on Friday gave approval to the vaccine developed by the University of Oxford and British-pharma giant AstraZeneca.

The approval for a COVID-19 vaccine in India is likely just around the corner, with the Drugs Controller General of India, Dr. VG Somani, indicating the country might begin the New Year with a vaccine in hand.

After US-based Pfizer and Pune's Serum Institute of India, Bharat Biotech has sought an emergency use approval for its coronavirus vaccine, named COVAXIN.

United States-based pharmaceutical giant Pfizer has sought emergency approval for its COVID-19 vaccine from India's drug regulator.

By early next week, AIIMS will submit a proposal to start the third phase of clinical trials of COVAXIN, a vaccine against coronavirus being developed by Bharat Biotech.

In a welcome piece of development, Serum Institute of India's CEO Adar Poonawalla said on Wednesday that the coronavirus vaccine, being developed by Oxford University, could be available for use in India by December 2020.

The Indian government is planning to provide vaccines to roughly 25 crore people by July 2021, Union Health Minister Dr. Harsh Vardhan said on Sunday.

In a major move, Bharat Biotech has signed an agreement to license a nasal COVID-19 vaccine developed by the Washington University School of Medicine in St. Louis, United States.

Even as TikTok, Oracle, and Walmart came close to finalizing a deal, China is not ready to let the service off the hook.

The Drugs Controller General of India (DCGI) has approved for commercial launch of a CRISPR-based test for COVID-19, called 'Feluda'.

As India reels under coronavirus catastrophe, Kiran Mazumdar Shaw, chairperson of Biocon Ltd., joined the long list of famous personalities to test positive for the highly-contagious disease.